Sunlenca (lenacapavir) received FDA approval as first-in-class, twice-yearly treatment option for people with multi-drug resistant HIV
On Dec. 22, 2022, Gilead Sciences announced that Sunlenca (lenacapavir), in combination with other antiretroviral(s) (ARV), had been…